← DPP-4 inhibitors × adverse events & safety

SynthesisEuropean review for medical and pharmacological sciences2022

Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis.

Y Ding et al.PubMed ↗Publisher ↗

What the trial testedas reported · 8,533 people · 2022

Range includes no effect

No clear effect on adverse events & safety

−2%−6% to +2%

Bigger than 1 in 10 for adverse events & safety

As reported

RR 0.98, 95% CI 0.94–1.02

Not counted

Lowered adverse events & safety

−45%−60% to −24%

Bigger than 8 in 10 for adverse events & safety

As reported

RR 0.55, 95% CI 0.40–0.76

Not counted

Lowered adverse events & safety

−28%−42% to −9%

Bigger than 6 in 10 for adverse events & safety

As reported

RR 0.72, 95% CI 0.58–0.91

Not counted

Raised adverse events & safety

+41%+6% to +88%

Bigger than 6 in 10 for adverse events & safety

As reported

RR 1.41, 95% CI 1.06–1.88

Four numbers in the abstract

the abstract, start to end

… risk of total adverse events (AEs) [RR=0.98, 95% CI (0.94,1.02), p=0.29], however there were significant statistical difference and did not increase the risk of diarrhea [RR=0.55, 95% CI (0.40, 0.76), p=0.0003] and Gastrointestinal (GI) disorders [RR=0.72, 95% CI (0.58, 0.91), p=0.006], but significantly increased risk of dizziness [RR=1.41, 95% CI (1.06, 1.88), p=0.02] …

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
RR 0.980.94–1.02
Adverse events & safety
RR 0.550.40–0.76
Adverse events & safety
RR 0.720.58–0.91
Adverse events & safety
RR 1.411.06–1.88
MetforminDPP-4 inhibitorsAdverse events & safety
1 / 3

10 papers cite it

2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 35503625